¤¸·Ó


¹Ï®Ñ

¥DÃD¹Ï®Ñ
¥N²zÁ`¸g¾P

Àu´f¬¡°Ê


¤¸·Ó¡G ¤ë¥¹Á¿®y > Á`Äý > ´¼¼z°]²£ºÞ²z»Pªk¨î

ÃÄ«~±M§Q»P³sµ²¡]¼v­µ½u¤Wª©¡^

ÃÄ«~±M§Q»P³sµ²¡]¼v­µ½u¤Wª©¡^

¡i¥DÁ¿ªÌ¡j¶¾¾_¦t¡Dªô«a³Ô¡DKevin E. Warner
¡i®Ñ¡@¸¹¡j 6B0195RM1
¡i¥Xª©ªÀ¡j ¤¸·Ó¥Xª©¤½¥q
¡i¥X¡@ª©¡j 2016/10
¡iª©¡@¦¸¡j 1
¡iISBN/ISSN¡j
¡i©w¡@»ù¡j600 ¤¸
¡i¯S¡@»ù¡j540 ¤¸
 
 
 Â²¤¶

ÃÄ«~±M§Q»P³sµ²


²£«~¤º®e¡G½u¤Wª©
µoªí¤é´Á¡G2015¦~11¤ë20¤é
¼v¤ùªø«×¡G¬ù1¤p®É

§¹¾ã¼v­µ¡þ¸ÕÅ¥▶▶▶¡i¥ß§Y«e©¹¡j


¡i¤º®e²¤¶¡j
¥D«ù¤H¡G¶¾¾_¦t¡þ¬Fªv¤j¾Çªk«ß¾Ç°|±Ð±Â
Á¿ÃD¤@¡GFORUM SELEC TION IN HATCH-WAXMAN ACTIONS
³ø§i¤H¡Gªô«a³Ô¡þ©ú´I´¼°]ºÞ²zÅU°Ý¦³­­¤½¥q¸ê²`ÅU°Ý
Á¿ÃD¤G¡GNavigating the Biosimilar Regulatory Framework
³ø§i¤H¡GKevin E. Warner¡þWinston & Strawn,LLP«ß®v


Á¿¡@ºõ
Á¿ÃD¢°¡G
(1) Branded Drug
(2) ANDA
(3) Jurisdiction
(4) Latest Case Law
(5) Proposed Arguments
Á¿ÃD2¡G
(1) Biosimilars vs. Generic Drugs
(2) The "Patent Dance"
(3) "Phase Two" Patents
(4) Other Pending Biosimilar Cases
(5) Recent U.S. Supreme Court Cases, Developments and Trends

2015¦~¥þ°ê¬ì§Þªk«ß¬ã°Q·|¥þ¥DÃD¦Cªí

¥DÃD¤@¡G±M§Q»P¶D³^
¡]¤@¡^§Ú°ê´¼°]ªA°È·~¤§²{ªp»Pºë¶i¤è¦V
¡]¤G¡^¬ü°ê±M§Q¶D³^³Ì·sµo®i
¡]¤T¡^¸Ø°ê±M§Q¶D³^
¡]¥|¡^±ÂÅv«´¬ù»P·s¥[©Y±M§Qµ¦²¤
¡]¤­¡^±ÂÅv«´¬ù»P±M§QÁp·ù
¡]¤»¡^¬ü°ê±M§Q¨î«×»P°ê»Ú±M§QÁp·ù
¡]¤C¡^±M§Q¨î«×»P¶D³^
¡]¤K¡^ÃÄ«~±M§Q»P³sµ²
¡]¤E¡^TPP¡BÃÄ«~±M§Q»P³sµ²
▶▶▶±M§Qªk¹Ï®Ñ±M°Ï
▶▶▶´¼¼z°]²£ºÞ²z»Pªk¨î¼v­µ±M°Ï

¥DÃD¤G¡G¶T©ö¥òµô»PÃÒ¨é¥Ç¸o
¡]¤@¡^°ê»Ú°Ó°È¥òµô»P¶D³^¥~ª§ºÝ¸Ñ¨M¾÷¨î
¡]¤G¡^°ê»Ú°Ó°È¥òµô³Ì·sµo®iÁͶÕ
¡]¤T¡^TPP»PÃÄ«~±M§Q
¡]¥|¡^Ävª§ªk
¡]¤­¡^Àç·~¯µ±K¥Ç¸o»PÃÒ¨é¥Ç¸o
▶▶▶¥ø·~ªk«ß¹Ï®Ñ±M°Ï
▶▶▶ª÷¿ÄºÊ²z»Pªk¨î¼v­µ±M°Ï

¥DÃD¤T¡GµÛ§@Åv»P°Ó¼Ð
¡]¤@¡^°Ó¼ÐÅv«OÅ@
¡]¤G¡^µÛ§@Åv¥ò¤¶¹ÎÅé¤Î­Ó¸ê«OÅ@
¡]¤T¡^µÛ§@Åv­×ªkÁͶդÀªR
▶▶▶µÛ§@Åvªk¹Ï®Ñ±M°Ï
▶▶▶´¼¼z°]²£ºÞ²z»Pªk¨î¼v­µ±M°Ï

¥DÃD¥|¡G­¹«~¦w¥þ»PÂåÀø
¡]¤@¡^ÂåÀø»P¤½½Ãªk¨î
¡]¤G¡^­¹«~¦w¥þ
¡]¤T¡^­¹«~¦w¥þ»P¤½¦@½Ã¥Í
▶▶▶Âå¨Æªk«ß¹Ï®Ñ±M°Ï
▶▶▶Âå¨Æªk«ß¼v­µ±M°Ï

¥DÃD¤­¡G¤j¼Æ¾Ú»P¸ê¦w
¡]¤@¡^¤j¼Æ¾Ú»P­Ó¤H¸ê®Æ«OÅ@
¡]¤G¡^¸ê³q°Tªk¤ÎÁô¨pÅv«OÅ@
¡]¤T¡^¤j¼Æ¾Ú»P¸ê³q°Tªk

¥DÃD¤»¡G³Ò°Êªk
³Ò°Êªk¨î¦]À³¬ì§Þ²£·~µo®i¤§½Õ¾A
▶▶▶³Ò°Êªk¹Ï®Ñ±M°Ï
▶▶▶³Ò°Êªk¼v­µ±M°Ï

 
 ª`·N¨Æ¶µ¡G
1. ±ý¿ïÁÊ¡i«ö½g¦C¦L¡j¡A½Ð¥ýÁʶR¡i¤ë¥¹ª¾ÃÑ®wÂI¼Æ¡j§Y¥i¦Û¦æ¤U¸ü¦C¦L¡C
2. ÁʶR¡i¤ë¥¹ª¾ÃÑ®w¡jªº·|­û¡A¦b±z§¹¦¨¥I´Ú¤âÄò¤§«á¡A§Ú­Ì±N©ó¤@¦Ü¤G­Ó¤u§@¤Ñ¤º¡A¥H email ±M¨ç³qª¾±z±Ò¥ÎÂI¼Æ¡C
¡@­Y¦³«æ»Ý¨Ï¥ÎªÌ¡A½Ð¬¢«ÈªA±M½u 886-2-23756688 ¤À¾÷ 502 ¡ã 505¡A§Ú­Ì±N¥H¡uÀH¿ï¦C¦L¡v¤è¦¡´£¨Ñ¡C
3. ½u¤WÁʮѨì³f¤C¤é¤º¡A¦p¹ï®ÑÄy¤º®e¦³¥ô¦óºÃ¼{¥²¶·´«³fªÌ¡A½Ð©ó¤C¤é¤º³s¦Pµo²¼±H¦^¥»¤½¥q§ó´«¡C
4. ®ÑÄy°h´«³f³B²z§@·~®É¶¡¬ù¤Q­Ó¤u§@¤Ñ ( ¤£§t¨Ò°²¤é )¡C
5. ¥Ñ©ó³f¹B¤½¥q°e³f¨ì©²»Ý¸gñ¦¬¤âÄò¡A½Ð°È¥²¯d¤U¦³¤H¥iñ¦¬¤§¦¬¥ó¦a§}¡AÁקK³f¥óº¢¯d³f¹B ¤½¥q©µÌX¦¬¥ó¡B®É¶¡·l¥¢¡C
6. ­Y±z¿ïÁʪº®ÑÄy¥]§t¹wÁʮѡA¥»¯¸±N±Ä§å¦¸±Hµo§@·~¡A«Ý¥X®Ñ«á¤@¨Ö±Hµo¡F­Y»Ý¤À¦¸±Hµo¡A°u¦¬ 80 ¤¸ª«¬y³B²z¶O¡C
7. 2016¦~1¤ë1¤é°_¡A¤ë¥¹ª¾ÃÑ®wÂI¼Æ¡B¤ë¥¹«~µû®a¡B¤¸·Ó¹q¤l®Ñ¡B¤ë¥¹Âø»x¨t¦C¹q¤lª©¤£¾A¥Î¤C¤ÑŲ½à´ÁªA°È¡C>>¸Ô²Ó»¡©ú<<
8. ¤¸·Óºô¸ô®Ñ©±«O¯d±µ¨ü­q³æ»P§_ªºÅv§Q¡C
9. ¤¸·Óºô¸ô®Ñ©±«ÈªA±M½u¡G886-2-2375-6688 ¤À¾÷ 502 ¡ã 505¡C


¤¸·ÓŪ®ÑÀ]
¤ë¥¹«~µû®a ¿P¤j¤¸·Ó¦W®a½×¾Â
¤ë¥¹ª¾ÃÑ®w ¤ë¥¹ªk«ß¤ÀªR®w
¤ë¥¹Âå¨Æªkºô ¤ë¥¹·|­p°]µ|ºô
´Á¥Z¼Æ¦ìªA°È ªÀ¸s¥­¥x ŪªÌªA°È Ãö©ó¤¸·Ó
ŪªÌªA°È±M½u¡G+886-2-23756688¡@¶Ç¯u¡G+886-2-23318496¡@«ÈªA«H½c
¦a§}¡G»O¥_¥«À]«e¸ô28 ¸¹ 7 ¼Ó¡@¤¸·Ó¥Xª©¦³­­¤½¥q¡@²Î½s¡G16604673
Copyright © ¤¸·Ó¥Xª© All rights reserved. ª©Åv©Ò¦³¡A¸T¤îÂà¶K¸`¿ý